Table 2. Characteristics of included studies.
| Trial | Patient (n) | Type of population | Clinical presentation | Type of statin | Statin regime before PCI | Statin regime after PCI | Follow up | PMI definition |
| Fujii et al. | 80 | Statin naive | Stable angina | Pravastatin | 4-week pretreatment with 20 mg/d before PCI VS no pretreatment | NA | In-hospital | TnI>5UNL |
| Yu et al. | 81 | Statin naive | NSTE-ACS | Atorvastatin | 80 mg 12 h before PCI+40 mg before PCI VS placebo group | Atorvastatin 20 mg/d | 30days | CK-MB>2UNL |
| Gao et al. | 117 | Statin naive | NSTE-ACS | Rosuvastatin | 20 mg 12 h before PCI +10 mg 2 h before PCI VS no treatment | Rosuvastatin 10 mg/d | 6months | CK-MB>3UNL |
| Jang et al. | 335 | Statin naive | NSTE-ACS | Atorvastatin | 80 mg 12 h and 40 mg 2 h before PCI VS no statin pretreatment | Atorvastatin 40 mg/day | 30days | CK-MB>3UNL |
| Zemánek et al. | 202 | Statin-treated | Stable angina | Atorvastatin | 7-day pre-treatment with 80 mg/d VS no statin pretreatment | NA | In-hospital | CK-MB>3UNL |
| ROMA Trial | 160 | Statin naive | Stable angina | Rosuvastatin | Rosuvastatin 40 mg within 24 h before PCI VS no statin | Rosuvastatin 20 mg/d | 12months | CK-MB>3UNL |
| ROMA II trial | 450 | Statin-treated | Stable angina | Atorvastatin; Rosuvastatin | Rosuvastatin 40 mg or Atorvastatin 80 mg 24 h before PCI VS no statin pretreatment | Rosuvastatin 20 mg/d Atorvastatin 40 mg/d | 12months | CK-MB>3UNL |
| Nafasi et al. | 190 | Statin-treated | Stable angina and recent MI | Atorvastatin | 80 mg within 24 h before PCI VS placebo within 24 h before PCI | NA | In-hospital | TnI>5UNL |
| Takano et al. | 210 | statin-treated and statin-naive | Stable angina | Rosuvastatin | 5–7day pretreatment with 20 mg/d before PCI VS 5–7day pretreatment with 2.50 mg before PCI | Rosuvastatin 10 mg/d AND rosuvastatin 2.5 mg/d | In-hospital | CK-MB>3UNL |
| Wang et al. | 125 | Statin naive | NSTE-ACS | Rosuvastatin | 20 mg 2–4 hours before PCI VS placebo before PCI | Rosuvastatin 10 mg/d | 30days | CK-MB>3UNL |
| Luo et al. | 67 | Statin naive | NSTE-ACS | Rosuvastatin | 20 mg 12 h before PCI+20 mg 2 h before PCI VS no Statin pretreatment | Rosuvastatin 10 mg/d | 30days | TnI>3UNL |
| Li et al. | 215 | statin-treated | Stable angina | Atorvastatin | 80 mg 12 h before PCI VS 20 mg 12 h before PCI | Atorvastatin 20 mg/d | 30days | NA |
PCI = percutaneous coronary intervention; CK-MB = creatine kinase-MB; UNL = upper normal limit of normal; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; ROMA trial = Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of periprocedural myocardial necrosis; ROMA II trial = Comparison of high reloading Rosuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of periprocedural myocardial necrosis; NA = not available.